VistaGen Therapeutics (VTGN) Projected to Release Earnings on Thursday

VistaGen Therapeutics (NASDAQ:VTGN) is expected to announce its Q2 2027 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of ($0.3750) per share and revenue of $0.50 million for the quarter. Individuals can check the company’s upcoming Q2 2027 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 5:00 PM ET.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06. The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $0.50 million. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. On average, analysts expect VistaGen Therapeutics to post ($1.45) EPS for the current fiscal year and ($1.54) EPS for the next fiscal year.

VistaGen Therapeutics Trading Up 9.7%

NASDAQ:VTGN opened at $0.18 on Thursday. The firm has a market cap of $8.18 million, a P/E ratio of -0.11 and a beta of 0.49. The stock’s 50 day simple moving average is $0.23 and its 200-day simple moving average is $0.44. VistaGen Therapeutics has a 12-month low of $0.17 and a 12-month high of $5.14.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Monday, August 31st. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Company Profile

Vistagen Therapeutics, Inc (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing therapies for central nervous system and neuropsychiatric disorders. The company focuses on intranasal treatments designed to act rapidly and address conditions for which patients may need alternatives to conventional systemic medicines.

Vistagen’s lead investigational product is fasedienol, also known as PH94B, a nasal spray being studied as a potential treatment for social anxiety disorder.